SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity.


Journal

EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 04 03 2021
revised: 07 05 2021
accepted: 07 05 2021
pubmed: 8 6 2021
medline: 2 7 2021
entrez: 7 6 2021
Statut: ppublish

Résumé

The SARS-CoV-2 pandemic currently prevails worldwide. To understand the immunological signature of SARS-CoV-2 infections and aid the search and evaluation of new treatment modalities and vaccines, comprehensive characterization of adaptive immune responses towards SARS-CoV-2 is needed. We included 203 recovered SARS-CoV-2 infected patients in Denmark between April 3 We report broad serological profiles within the cohort, detecting antibody binding to other human coronaviruses. 202(>99%) participants had SARS-CoV-2 specific antibodies, with SARS-CoV-2 neutralization and spike-ACE2 receptor interaction blocking observed in 193(95%) individuals. A significant positive correlation (r=0.7804) between spike-ACE2 blocking antibody titers and neutralization potency was observed. Further, SARS-CoV-2 specific CD8 The viral surface spike protein was identified as the dominant target for both neutralizing antibodies and CD8 This study was supported by the Danish Ministry for Research and Education (grant# 0238-00001B) and The Danish Innovation Fund (grant# 0208-00018B).

Sections du résumé

BACKGROUND BACKGROUND
The SARS-CoV-2 pandemic currently prevails worldwide. To understand the immunological signature of SARS-CoV-2 infections and aid the search and evaluation of new treatment modalities and vaccines, comprehensive characterization of adaptive immune responses towards SARS-CoV-2 is needed.
METHODS METHODS
We included 203 recovered SARS-CoV-2 infected patients in Denmark between April 3
FINDINGS RESULTS
We report broad serological profiles within the cohort, detecting antibody binding to other human coronaviruses. 202(>99%) participants had SARS-CoV-2 specific antibodies, with SARS-CoV-2 neutralization and spike-ACE2 receptor interaction blocking observed in 193(95%) individuals. A significant positive correlation (r=0.7804) between spike-ACE2 blocking antibody titers and neutralization potency was observed. Further, SARS-CoV-2 specific CD8
INTERPRETATION CONCLUSIONS
The viral surface spike protein was identified as the dominant target for both neutralizing antibodies and CD8
FUNDING BACKGROUND
This study was supported by the Danish Ministry for Research and Education (grant# 0238-00001B) and The Danish Innovation Fund (grant# 0208-00018B).

Identifiants

pubmed: 34098342
pii: S2352-3964(21)00203-6
doi: 10.1016/j.ebiom.2021.103410
pmc: PMC8176920
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103410

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Stine Sf Nielsen (SS)

Department of Infectious Diseases, Aarhus University Hospital, Denmark; Department of Clinical Medicine, Aarhus University, Denmark.

Line K Vibholm (LK)

Department of Infectious Diseases, Aarhus University Hospital, Denmark.

Ida Monrad (I)

Department of Infectious Diseases, Aarhus University Hospital, Denmark.

Rikke Olesen (R)

Department of Infectious Diseases, Aarhus University Hospital, Denmark.

Giacomo S Frattari (GS)

Department of Infectious Diseases, Aarhus University Hospital, Denmark.

Marie H Pahus (MH)

Department of Clinical Medicine, Aarhus University, Denmark.

Jesper F Højen (JF)

Department of Infectious Diseases, Aarhus University Hospital, Denmark.

Jesper D Gunst (JD)

Department of Infectious Diseases, Aarhus University Hospital, Denmark; Department of Clinical Medicine, Aarhus University, Denmark.

Christian Erikstrup (C)

Department of Clinical Immunology, Aarhus University Hospital, Denmark.

Andreas Holleufer (A)

Department of Molecular Biology and Genetics, Aarhus University, Denmark.

Rune Hartmann (R)

Department of Molecular Biology and Genetics, Aarhus University, Denmark.

Lars Østergaard (L)

Department of Infectious Diseases, Aarhus University Hospital, Denmark; Department of Clinical Medicine, Aarhus University, Denmark.

Ole S Søgaard (OS)

Department of Infectious Diseases, Aarhus University Hospital, Denmark; Department of Clinical Medicine, Aarhus University, Denmark.

Mariane H Schleimann (MH)

Department of Infectious Diseases, Aarhus University Hospital, Denmark.

Martin Tolstrup (M)

Department of Infectious Diseases, Aarhus University Hospital, Denmark; Department of Clinical Medicine, Aarhus University, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH